Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study

Other illness

• If ANY study exclusion criteria are met, the patient is excluded from the study and cannot be enrolled (recruitment failure).
• Subject is implanted with a cardiac implantable electronic device (CIED) with pacing capability.
• Have a life expectancy of less than 1 year due to any condition.

Other

• Subject is currently participating in another clinical investigation that could confound the results of this study, without documented pre-approval from Abbott.

• Patients must meet ALL study inclusion criteria to participate in the study.
• Have an approved indication AND are scheduled to receive an Assert-IQTM ICM device prior to enrollment in the study.
• Diagnosed with symptomatic, drug-refractory paroxysmal or persistent AF prior to enrollment in the study and scheduled to undergo a first-time atrial fibrillation ablation.
• Have a cellular phone or the ability or willing to use a mobile transmitter that is compatible with the myMerlin™ App and able to communicate with the Assert-IQTM ICM device. If a subject doesn't have a cell phone or loses their cell phone, then the site can provide a mobile transmitter to the subject. The study will not provide cell phones.
• Are 18 years of age or older, or of legal age to give informed consent specific to state and national law.
• Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations.